Low-molecular weight heparin (
LMWH) has been widely used as a systemic
anticoagulant during
percutaneous coronary intervention. In this study,
LMWH was covalently immobilized to the surface of a
cobalt chromium reservoir-based
sirolimus-eluting
stent to create a nonelutable nanoscale coating for enhanced thromboresistance. Toludine-blue stained
stents revealed uniform
heparin coverage on all surfaces of the
stent. Scanning electron microscopy of
stent strut cross-sections showed identical coating thickness on all sides; while the thickness was determined to be 320 nm by a focus-ion beam system. Secondary ion mass spectrometry showed constant concentrations of O, N, and S atoms throughout the depth of the surface, confirming the uniformity of the
heparin coating. The nonelutable nature of the coating was confirmed in a modified
Factor Xa inhibition assay which showed the
stent had an equivalent of 3-5
heparin units/cm(2), while no elutable
heparin was detected in wash solutions. The
antithrombin binding capacity of the immobilized
heparin was determined to be 60-80 pmol/cm(2) in an
antithrombin uptake assay. The enhanced thromboresistance of the
heparin coating was demonstrated in an in-vitro bovine blood flow loop which showed minimal visual
thrombus accumulation and 95% reduction in platelet deposition compared to uncoated control
stents.
Drug-eluting stents with such nonelutable
LMWH coating would represent a significant advance in the treatment of patients with complex lesions who are at increased risk of developing
stent thrombosis.